CTOs on the Move

Bleep Sleep

www.bleepsleep.com

 
Fewer than 50% of Sleep Apnea patients stick with a CPAP solution – including us. So we decided to do something about it. Not sleeping sucks. Not sleeping and spending a fortune on CPAP devices that leak, fall off or leave marks on your face sucks even worse. That`s why we invented the DreamPort Sleep Solution – the world`s first-ever maskless CPAP device. The result is the smallest, lightest, most ergonomically accommodating CPAP solution on the market – a device that fits comfortably and doesn`t restrict your movement – enabling patients to get a better night`s sleep. Our goal is ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.bleepsleep.com
  • 11312 US 15-501 North Suite 107-206
    Chapel Hill, NC USA 27517
  • Phone: 919.619.7170

Executives

Name Title Contact Details

Similar Companies

Sanitec Industries

Sanitec Industries is a Sun Valley, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Biolinq

Biolinq develops skin-applied electrochemical sensors that analyze body fluids to provide actionable health information. Get blood level info, without accessing blood.

ALung Technologies

ALung Technologies has developed the Hemolung Respiratory Assist System (RAS), a dialysis-like alternative or supplement to mechanical ventilation. The Hemolung RAS provides Respiratory Dialysis,a simple, less invasive form of extracorporeal CO2 removal. By removing carbon dioxide and delivering oxygen directly to the blood, the Hemolung RAS allows the patients lungs to rest and heal. Applications of the device include preventing intubation in acute exacerbation of chronic obstructive pulmonary disease (COPD) and enabling ultra-protective ventilation in acute respiratory distress syndrome (ARDS).

Gallini S.R.L.

Gallini S.R.L. is a Grand Rapids, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

HeartFlow

HeartFlow is a medical technology company transforming the way cardiovascular disease is diagnosed and treated. With our HeartFlow Analysis, a non-invasive personalized cardiac test, physicians are able to make better care decisions for their patients with suspected coronary artery disease--the number one killer of men and women worldwide. HeartFlow is backed by decades of scientific research and development and leverages the latest advancements in technology to help set a new standard of care for diagnosing cardiovascular care worldwide. Cleared for use in the United States, Canada, Europe and Japan and with offices in Redwood City, Austin, London and Japan, HeartFlow`s footprint is growing rapidly. HeartFlow has received more than $240 million dollars in funding in a recent Series E financing round, is pre-IPO and leverages the latest technology including deep learning and computational fluid dynamics. We try to embody the best of both technology and healthcare companies and hire people who are passionate about living our mission to save lives, improve the patient experience and reduce the overall cost of care.